ibidi introduces LifeAct for Actin cytoskeleton visualization

Munich, (PresseBox) - ibidi GmbH, a supplier of solutions for Bio-Microscopy, releases LifeAct, a novel probe for visualization of Actin cytoskeleton organization and dynamics.

In the past, Actin markers visualized Actin but also disturbed the acitivity of the protein. In contrast, the new Actin marker LifeAct from ibidi binds to the structure protein without constraining its activity. Only 17 amino acids long, LifeAct is linked to a fluorescent dye which allows the tracking of development and movement of Actin structures. Originating from yeast, the marker has also been successfully utilized in kidney cells, white blood cells, neurons and a multitude of further cell types and tissues.

LifeAct is available as a plasmid coding for the peptide and a red or green fluorescent protein. The plasmid is used for easy transfection of various cell types and for the generation of stably expressing cell lines.

"LifeAct perfectly fits in our product portfolio on cell microscopy, immuno­fluorescence and cell based assays", commented Dr. Valentin Kahl, cofounder and managing director of ibidi GmbH. "With this marker our customers are able to easily visualize and quantify the movement of cells. This technology will be especially useful for studies on angiogenesis, but also in oncology, neurology and immunology."

ibidi GmbH

ibidi® GmbH, Munich, Germany, develops, produces and distributes micro-Slides (µ- Slides), a "Labona-Slide®" technology for the image based analysis of cells. The µ-Slides represent a new family of devices for the functional analysis of living cells. The µ-Slide product family consists of different slide types for cellculture and high end optical microscopy.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Lieber Künstliche Intelligenz als menschliche Dummheit?

„Wenn sie an Ihr Pri­vat­le­ben den­ken: In wel­chen der fol­gen­den Si­tua­tio­nen wür­den Sie eher die Ent­schei­dung ei­ner Künst­li­chen In­tel­li­genz ak­zep­tie­ren als die ei­nes Men­schen?“ So lau­te­te die Fra­ge­stel­lung ei­ner Um­fra­ge, die von Bit­kom Re­se­arch durch­ge­führt wur­de.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.